W2O has acquired research consulting firm Elysia Group.
Elysia conducts health economic and outcomes research and operates in New York, Shanghai and Taipei, Taiwan. It provides health economic modeling, database analysis and other healthcare-related research services to the pharmaceutical and medical device industries, according to the firm’s website.
Elysia founders Bruce Wang and Wesley Furnback will serve as health economics and real-world evidence practice leaders at W2O and report to Rita Glaze, practice leader for commercial strategy and market access, the San Francisco-based agency said in a statement.
Wang and Furnback will also coordinate efforts for W2O with Discern Health, which it acquired in July. Discern advises healthcare clients on performance measures and payment models.
W2O also bought Symplur, a healthcare-specific social media analytics platform in April and healthcare advertising and medical education firm 21Grams at the start of the year.
W2O’s revenue increased by 23% last year to $200 million, according to MM+M’s Agency 100.
